argenex SE (ARGX) vs Royalty Pharma PLC (RPRX)
argenex SE and Royalty Pharma PLC are both Biotechnology companies. argenex SE is the larger, with a market value of $60.2B against $34.4B — 1.8× the size. argenex SE trades at the lower P/E: 34.6× against 40.1×. argenex SE grew revenue faster over the last twelve months: 70.6% against 10.0%. argenex SE has the higher net margin (32.2% vs 32.0%) and the higher return on invested capital (20.7% vs 5.28%). Across the 22 metrics below, argenex SE leads on 14 and Royalty Pharma PLC on 8.
Valuation
Profitability
| Metric | ARGX | RPRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 90.15% | 100.00% | 65.16% |
| Operating margin | 30.06% | 59.61% | 0.00% |
| Net margin | 32.20% | 32.02% | 0.00% |
| Free cash flow margin | 25.87% | 51.66% | 0.00% |
| Return on equity | 27.07% | 8.42% | (57.72%) |
| Return on assets | 19.95% | 4.26% | (49.22%) |
| Return on invested capital | 20.71% | 5.28% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack